We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Androgen Receptor May Impact Prostate Cancer Test

By LabMedica International staff writers
Posted on 14 Nov 2012
The study of a specific part of the male DNA makes it possible to refine the interpretation of prostate-specific antigen (PSA) tests, which could reduce the risk of men being treated for prostate cancer unnecessarily.

A PSA test measures the level of the antigen in the blood, and raised PSA can signal an increased risk of cancer; however, this is not the case for everyone. More...
The problem is that there is no reliable way to separate those with naturally high levels of PSA from those at increased risk of prostate cancer.

A study conducted at Lund University (Sweden) shows how a man's genetic characteristics can affect the androgen receptor, a protein that has an important function in the male reproductive system. It regulates the effect of testosterone and controls production of prostate-specific antigen. The study is based on samples from around 400 men from Sweden and Norway.

The scientists studied healthy men in different age groups and discovered a connection between PSA levels in the blood and DNA structure of the androgen receptor. The highest PSA levels were found in the men with the most common variant of the androgen receptor that was within the largest group of men.

Christel Björk, PhD, a doctoral student at the Department of Clinical Sciences at Lund University, said, “If we know that a man has a naturally high level of PSA, this can be taken into account in a PSA test, and the patient may be able to avoid arduous treatment with a risk of side-effects." Both the PSA level and the genetic characteristics can be identified with a blood test. Before the results can be implemented for PSA tests in the health service, the study must be repeated on a larger group.

Related Links:

Lund University



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Modular Hemostasis Automation Solution
CN Track
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.